BioSpace News Archive

KemPharm, Inc. announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders detailing the company’s strategic focus on Central Nervous System /Rare Disease indications, as well as an updated clinical development strategy.

Marker Therapeutics, Inc. announced that the United States Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen -specific T cell product optimized for the treatment of patients with pancreatic cancer.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Australia’s Therapeutic Goods Administration has granted approval for provisional registration of NVX-CoV2373, Novavax’ COVID-19 vaccine, for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in individuals 18 years of age and older.

The expanding number of street mishaps across the globe is one of the main considerations driving the market.

E-prescription is a type of electronic prescribing technology that enables doctors to become paperless by transmitting prescriptions in a digital format rather than handwriting them.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to Fact.MR, the global intravascular catheters market is predicted to grow steadily between 2021 and 2031.

Biosimilars can be defined as a biologic medical product, which is considered to be similar to already approved biologic.

According to Emergen Research, the global human microbiome market size was USD 458.33 million in 2020 and is expected to reach USD 2,057.81 million in 2028 and register a revenue CAGR of 21.8% during the forecast period, 2021-2028.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.

Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today that its Drug Product Services is participating in the Real-World Handling of Protein Drugs - Exploration, Evaluation and Education (RealHOPE) project.